Aktien in diesem Artikel
Indizes in diesem Artikel
Alcon Inc. ALC recently inked a deal to acquire EYSUVIS (loteprednol etabonate suspension) 0.25% pharmaceutical eye drops from Kala Pharmaceuticals
, Inc. The acquisition adds to Alcon’s Systane family of eye drops. It complements the newly-launched Systane Preservative-Free formulations by expanding treatment options for dry eye.Alcon will also acquire INVELTYS (loteprednol etabonate suspension) 1%, the only corticosteroid for twice-a-day treatment of post-operative inflammation and pain following ocular surgery, as part of the agreement.The EYSUVIS will provide Eye Care Professionals (ECPs) with
a short-term treatment alternative to help alleviate dry eye disease. According to Alcon’s research, 20-25% of dry eye patients have acute dry eye episodes twice a year, on average. During these periods of acute dry eye, ECPs may prescribe EYSUVIS, which is a corticosteroid.Image Source: Zacks Investment ResearchThe latest acquisition is likely to fortify Alcon’s growing ophthalmic eye drop portfolio.Few Words on EYSUVISThe EYSUVIS was authorized by the FDA in January 2021 as the first and only corticosteroid indicated for the treatment of the signs and symptoms of dry eye disease for up to two weeks. The prescription therapy uses AMPPLIFY, a proprietary drug delivery technology, to improve penetration of loteprednol etabonate into targeted tissue on the ocular surface, thus helping prevent flares related to dry eye disease.Per management, the EYSUVIS is a natural fit for its newly-formed ophthalmic eye drop sales force in the United States. The company is well-positioned to grow the acute dry eye treatment market, leveraging its strong expertise in market access and commercial execution.Financial Terms of the AgreementThe terms of the agreement require Alcon to pay $60 million in upfront consideration to Kala Pharmaceuticals, Inc. Alcon may also be needed to make additional contingent payments if certain commercial milestones are met. The transaction is expected to close in the third quarter of 2022, subject to fulfillment of customary closing conditions, including regulatory approval.As a result of the agreement, Alcon’s full-year guidance for 2022 remains unchanged.Industry ProspectsPer a report published in Mordor Intelligence, the dry eye disease market is expected to see a CAGR of nearly 5.12% during 2022-2027. Factors such as aging, decrease in supportive hormones, systemic inflammatory diseases, ocular surface diseases or surgeries that affect the cholinergic nerves can be attributable to the prevalence of dry eye-related diseases.Given the substantial market prospects, Alcon’s acquisition of EYSUVIS for dry eye relief seems well-timed.Notable DevelopmentsIn March 2022, Alcon launched its Clareon family of intraocular lenses (IOLs) in the United States. Based on Alcon’s advanced IOL material, Clareon claims to deliver better visual outcomes with long-lasting clarity. With the latest launch, ClareonMonofocal, ClareonPanOptix, ClareonPanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.In January 2022, Alcon noted the addition to its advanced portfolio of dry eye products with the European launch of Systane Complete Preservative-Free Lubricant Eye Drops, available in an easy-to-use, multi-dose bottle. The Systane Complete Preservative-Free expands Alcon’s multi-dose, preservative-free portfolio to include an all-in-one solution for patients with dry eye symptoms.In the same month, the company launched the DAILIES TOTAL1 for Astigmatism-- the first and only Water Gradient contact lens for astigmatism patients. This launch expands Alcon’s premium, daily disposable lenses, including the DAILIES TOTAL1 (sphere) and DAILIES TOTAL1 Multifocal. The DAILIES TOTAL1 for Astigmatism contact lenses will be offered in the United States beginning in March.Share Price PerformanceThe stock has outperformed its industry in the past year. It has gained 5.6% versus the industry’s 16.8% fall.Zacks Rank and Key PicksCurrently, Alcon carries a Zacks Rank #3 (Hold).A few better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Medpace Holdings, Inc. MEDP and UnitedHealth Group Incorporated UNH.AMN Healthcare has a long-term earnings growth rate of 1.1%. The company surpassed earnings estimates in the trailing four quarters, delivering a surprise of 15.6%, on average. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.AMN Healthcare has outperformed its industry in the past year. AMN has declined 1.8% versus the industry’s 63% fall.Medpace has a historical growth rate of 27.3%. Medpace’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.1%. It currently has a Zacks Rank #2 (Buy).Medpace has outperformed its industry in the past year. MEDP has declined 20.3% against the industry’s 63% fall.UnitedHealth has an estimated long-term growth rate of 14.8%. UnitedHealth’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.7%. It currently carries a Zacks Rank #2.UnitedHealth has outperformed the industry over the past year. UNH has gained 18.2% compared with 16.2% industry growth in the said period.5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Alcon (ALC): Free Stock Analysis Report AMN Healthcare Services Inc (AMN): Free Stock Analysis Report Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment ResearchWeiter zum vollständigen Artikel bei "Zacks"
Ausgewählte Hebelprodukte auf Kala Pharmaceuticals Inc Registered Shs
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Kala Pharmaceuticals Inc Registered Shs